Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.

Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, Fan Y, Gruber TA, Baker S, Klco J, Rubnitz JE, Pounds S, Lamba JK.

Leukemia. 2019 Oct 23. doi: 10.1038/s41375-019-0604-8. [Epub ahead of print]

PMID:
31645648
2.

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.

Drusbosky LM, Singh NK, Hawkins KE, Salan C, Turcotte M, Wise EA, Meacham A, Vijay V, Anderson GG, Kim CC, Radhakrishnan S, Ullal Y, Talawdekar A, Sikora H, Nair P, Khanna-Gupta A, Abbasi T, Vali S, Guha S, Farhadfar N, Murthy HS, Horn BN, Leather HL, Castillo P, Tucker C, Cline C, Pettiford L, Lamba JK, Moreb JS, Brown RA, Norkin M, Hiemenz JW, Hsu JW, Slayton WB, Wingard JR, Cogle CR.

Blood Adv. 2019 Jun 25;3(12):1837-1847. doi: 10.1182/bloodadvances.2018028316.

3.

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.

Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, Lamba JK.

Blood Cancer J. 2019 May 21;9(6):51. doi: 10.1038/s41408-019-0211-y.

4.

MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.

Bhise NS, Elsayed AH, Cao X, Pounds S, Lamba JK.

Genes (Basel). 2019 Apr 24;10(4). pii: E319. doi: 10.3390/genes10040319.

5.

Pharmacogenomics of osteonecrosis of the jaw.

Yang G, Singh S, Chen Y, Hamadeh IS, Langaee T, McDonough CW, Holliday LS, Lamba JK, Moreb JS, Katz J, Gong Y.

Bone. 2019 Jul;124:75-82. doi: 10.1016/j.bone.2019.04.010. Epub 2019 Apr 22. Review.

6.

Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.

Lin KH, Xie A, Rutter JC, Ahn YR, Lloyd-Cowden JM, Nichols AG, Soderquist RS, Koves TR, Muoio DM, MacIver NJ, Lamba JK, Pardee TS, McCall CM, Rizzieri DA, Wood KC.

Cell Metab. 2019 May 7;29(5):1217-1231.e7. doi: 10.1016/j.cmet.2019.01.011. Epub 2019 Feb 14.

PMID:
30773463
7.

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.

Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, Lamba JK.

Leuk Lymphoma. 2019 Sep;60(9):2287-2290. doi: 10.1080/10428194.2019.1569232. Epub 2019 Feb 5. No abstract available.

PMID:
30721105
8.

Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML.

Bargal SA, Rafiee R, Crews KR, Wu H, Cao X, Rubnitz JE, Ribeiro RC, Downing JR, Pounds SB, Lamba JK.

Oncotarget. 2018 Oct 9;9(79):34859-34875. doi: 10.18632/oncotarget.26163. eCollection 2018 Oct 9.

9.

Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.

Lamba JK, Cao X, Raimondi SC, Rafiee R, Downing JR, Shi L, Gruber T, Ribeiro RC, Rubnitz JE, Pounds SB.

Oncotarget. 2018 Jul 13;9(54):30473. doi: 10.18632/oncotarget.25792. eCollection 2018 Jul 13.

10.

Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.

Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK.

Pharmacogenomics. 2018 Sep 1;19(14):1101-1110. doi: 10.2217/pgs-2018-0086. Epub 2018 Aug 8.

11.

Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Gbadamosi M, Meshinchi S, Lamba JK.

Future Oncol. 2018 Dec;14(30):3199-3213. doi: 10.2217/fon-2018-0325. Epub 2018 Jul 24.

12.

Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.

Lamba JK, Cao X, Raimondi SC, Rafiee R, Downing JR, Lei S, Gruber T, Ribeiro RC, Rubnitz JE, Pounds SB.

Oncotarget. 2018 Jun 1;9(42):26711-26723. doi: 10.18632/oncotarget.25475. eCollection 2018 Jun 1. Erratum in: Oncotarget. 2018 Jul 13;9(54):30473.

13.

CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.

Lamba JK, Voigt AP, Chauhan L, Shin M, Aplenc R, Eidenschink Brodersen L, Gamis AS, Meshinchi S, Loken MR.

Leuk Lymphoma. 2018 Sep;59(9):2250-2253. doi: 10.1080/10428194.2017.1421756. Epub 2018 Jan 10. No abstract available.

PMID:
29320902
14.

Retracted: Influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on cytarabine cytotoxicity in different populations.

Wang Y, Lamba JK.

J Clin Pharm Ther. 2017 Nov 21. doi: 10.1111/jcpt.12653. [Epub ahead of print] Retraction in: J Clin Pharm Ther. 2018 Apr;43(2):312.

PMID:
29164635
15.

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.

J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23.

16.

Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.

Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR.

Leuk Res. 2017 Jan;52:1-7. doi: 10.1016/j.leukres.2016.11.004. Epub 2016 Nov 6.

17.

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.

Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, Lamba JK, McIntosh MW, Meshinchi S, Walter RB.

Oncotarget. 2016 Jul 12;7(28):43281-43294. doi: 10.18632/oncotarget.9674.

18.

Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.

Fridley BL, Ghosh TM, Wang A, Raghavan R, Dai J, Goode EL, Lamba JK.

Front Genet. 2016 Mar 22;7:37. doi: 10.3389/fgene.2016.00037. eCollection 2016.

19.

MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients.

Bhise NS, Chauhan L, Shin M, Cao X, Pounds S, Lamba V, Lamba JK.

Front Pharmacol. 2016 Jan 28;6:324. doi: 10.3389/fphar.2015.00324. eCollection 2015.

20.

Clinical significance of in vivo cytarabine-induced gene expression signature in AML.

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE.

Leuk Lymphoma. 2016;57(4):909-20. doi: 10.3109/10428194.2015.1086918. Epub 2015 Oct 16.

21.

Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity.

Chauhan L, Jenkins GD, Bhise N, Feldberg T, Mitra-Ghosh T, Fridley BL, Lamba JK.

BMC Genomics. 2015 Jun 30;16:483. doi: 10.1186/s12864-015-1614-1.

22.

Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.

Bachanova V, Shanley R, Malik F, Chauhan L, Lamba V, Weisdorf DJ, Burns LJ, Lamba JK.

Biol Blood Marrow Transplant. 2015 May;21(5):944-8. doi: 10.1016/j.bbmt.2015.02.001. Epub 2015 Feb 10.

23.

Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.

Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P.

Pharmacogenomics. 2014;15(12):1565-74. doi: 10.2217/pgs.14.107.

24.

A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.

Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS.

Am J Hematol. 2014 Sep;89(9):889-95. doi: 10.1002/ajh.23778. Epub 2014 Jun 27.

25.

Identification of suitable reference genes for hepatic microRNA quantitation.

Lamba V, Ghodke-Puranik Y, Guan W, Lamba JK.

BMC Res Notes. 2014 Mar 7;7:129. doi: 10.1186/1756-0500-7-129.

26.

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN.

Br J Cancer. 2014 Jan 21;110(2):304-12. doi: 10.1038/bjc.2013.738. Epub 2013 Dec 3.

27.

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK.

Pharmacogenomics. 2013 Sep;14(12):1449-66. doi: 10.2217/pgs.13.131.

28.

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.

Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME.

Blood. 2013 May 23;121(21):4366-76. doi: 10.1182/blood-2012-10-464149. Epub 2013 Mar 28.

29.

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.

Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshinchi S, Lamba JK.

Clin Cancer Res. 2013 Mar 15;19(6):1620-7. doi: 10.1158/1078-0432.CCR-12-3115. Epub 2013 Feb 26.

30.

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE.

Pharmacogenet Genomics. 2013 Apr;23(4):236-41. doi: 10.1097/FPC.0b013e32835ea0b2. No abstract available.

31.

Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, Leppik IE, Lamba JK.

Pharmacogenomics. 2013 Jan;14(1):35-45. doi: 10.2217/pgs.12.180.

32.

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.

Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK.

Pharmacogenomics. 2012 Jul;13(9):1009-21. doi: 10.2217/pgs.12.81.

PMID:
22838949
33.

Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.

Thirumaran RK, Lamba JK, Kim RB, Urquhart BL, Gregor JC, Chande N, Fan Y, Qi A, Cheng C, Thummel KE, Hall SD, Schuetz EG.

Biochem Pharmacol. 2012 Jul 1;84(1):104-12. doi: 10.1016/j.bcp.2012.03.017. Epub 2012 Mar 30.

34.

Pharmacogenomics of cytarabine in childhood leukemia.

Lamba JK.

Pharmacogenomics. 2011 Dec;12(12):1629-32. doi: 10.2217/pgs.11.148. No abstract available.

PMID:
22118048
35.

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien HC, Weigel R, Tauzie J, Shumba I, Lamba JK, Schuetz EG, McLeod HL, Kashuba AD, Corbett AH.

Pharmacogenomics. 2012 Jan;13(1):113-21. doi: 10.2217/pgs.11.132. Epub 2011 Nov 23.

36.

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK.

J Pharmacol Exp Ther. 2011 Oct;339(1):9-23. doi: 10.1124/jpet.111.182873. Epub 2011 Jun 28.

37.

Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study.

Mitra AK, Crews K, Pounds S, Cao X, Downing JR, Raimondi S, Campana D, Ribeiro RC, Rubnitz JE, Lamba JK.

Leukemia. 2011 Aug;25(8):1354-6. doi: 10.1038/leu.2011.74. Epub 2011 Apr 12. No abstract available.

38.

Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.

Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC.

Pharmacogenomics. 2011 Mar;12(3):327-39. doi: 10.2217/pgs.10.191.

39.

PharmGKB summary: very important pharmacogene information for CYP2B6.

Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB.

Pharmacogenet Genomics. 2010 Aug;20(8):520-3. No abstract available.

40.

CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

Chaudhry AS, Urban TJ, Lamba JK, Birnbaum AK, Remmel RP, Subramanian M, Strom S, You JH, Kasperaviciute D, Catarino CB, Radtke RA, Sisodiya SM, Goldstein DB, Schuetz EG.

J Pharmacol Exp Ther. 2010 Feb;332(2):599-611. doi: 10.1124/jpet.109.161026. Epub 2009 Oct 23.

41.

Genetic factors influencing cytarabine therapy.

Lamba JK.

Pharmacogenomics. 2009 Oct;10(10):1657-74. doi: 10.2217/pgs.09.118. Review.

42.

Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.

Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, Dolan ME.

Blood. 2009 Mar 5;113(10):2145-53. doi: 10.1182/blood-2008-05-154302. Epub 2008 Dec 24.

43.

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.

Lamba JK, Pounds S, Cao X, Downing JR, Campana D, Ribeiro RC, Pui CH, Rubnitz JE.

Leukemia. 2009 Feb;23(2):402-4. doi: 10.1038/leu.2008.185. Epub 2008 Jul 10. No abstract available.

44.

The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Roberts PJ, Rollins KD, Kashuba AD, Paine MF, Nelsen AC, Williams EE, Moran C, Lamba JK, Schuetz EG, Hawke RL.

Drug Metab Dispos. 2008 Aug;36(8):1465-9. doi: 10.1124/dmd.107.020065. Epub 2008 May 19.

45.

Pharmacogenetics of the constitutive androstane receptor.

Lamba JK.

Pharmacogenomics. 2008 Jan;9(1):71-83. Review.

PMID:
18154449
46.

The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.

Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF.

Drug Metab Dispos. 2008 Jan;36(1):146-54. Epub 2007 Oct 22.

PMID:
17954524
47.

Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.

Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R.

J Pharmacol Exp Ther. 2007 Dec;323(3):935-45. Epub 2007 Sep 12.

PMID:
17855478
48.

Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.

Lamba JK, Chen X, Lan LB, Kim JW, Wei Wang X, Relling MV, Kazuto Y, Watkins PB, Strom S, Sun D, Schuetz JD, Schuetz EG.

Pharmacogenet Genomics. 2006 Jun;16(6):415-27.

PMID:
16708050
49.

G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression.

Song P, Lamba JK, Zhang L, Schuetz E, Shukla N, Meibohm B, Yates CR.

J Clin Pharmacol. 2006 Mar;46(3):373-9. No abstract available.

PMID:
16490813
50.

PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators.

Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S, Schuetz EG.

Toxicol Appl Pharmacol. 2004 Sep 15;199(3):251-65.

PMID:
15364541

Supplemental Content

Loading ...
Support Center